Advertisement.

OXBDF Projected Dividend Yield

Ord GBP 0.50/Oxford BioMedica Plc (United Kingdom) ( OTCBB : OXBDF )

Oxford Biomedica developes gene and cell therapy with a focused on lentiviral vector research, development and bioprocessing. Co. has built a lentiviral vector delivery system, LentiVector® platform, which Co. utilizes to develop in vivo and ex vivo products both in-house and with partners. Co. has a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, liver and CNS disorders. Co.'s partnered products includes AXO-Lenti-PD, which is a gene-based treatment for Parkinson's disease; SAR422459, which is a gene-based therapy for the treatment of Stargardt disease; and SAR421869, which is a gene-based therapy for the treatment of Usher syndrome 1B.

21 YEAR PERFORMANCE RESULTS

OXBDF Dividend History Detail
OXBDF Dividend News
OXBDF Competitors News

# of Shares: 0

Closing Price: 5.32

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000